Blood test monitoring for children with leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be younger than 18 years old when diagnosed with leukemia.
- You must have acute lymphoblastic leukemia, acute myeloid leukemia, or mixed phenotype acute leukemia.
- You need to have had a special blood test (called ctDNA) done as part of your care.
- You need to have had a bone marrow test (like MFC-MRD, ddPCR, or RNA sequencing) done at the same time.
- If you are joining the part of the study that looks ahead, your parent or guardian must sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This trial checks a blood test called “ctDNA” (tiny pieces of leukemia DNA in blood) after chemotherapy. It may help doctors understand how well treatment is working in older adults with acute leukemia.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.